 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H34N4O3S |
| Molar mass | 422.59 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RQ-00202730 is abenzimidazole deriveddrug that acts as a potent and highly selectiveagonist for the CB2cannabinoid receptor, with a Ki value of 19nM at CB2 and more than 4000x selectivity over CB1, though it also shows some activity as an antagonist of the unrelated 5-HT2Bserotonin receptor. It hasanalgesic andantiinflammatory effects in animal studies, and was developed for the treatment ofirritable bowel syndrome, but was ultimately discontinued from development following disappointing results in Phase IIclinical trials.[1][2][3]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
